EASL 2012 - Annual Meeting of European Association for the Study of the Liver

A Smart + Strong Site
Subscribe to:
• Hepatitis E-newsletter
Join Us:
HIGHLIGHTS
What you need to know
> Blogs > Hep Exclusives > Hepatitis News > Lessons


Safety Edge
Peg-IFN lambda has far fewer side effects vs. standard peg-IFN.


Partnership Potential
BMS/Gilead hep C drug combo show high cure rate potential.


GS-7977 vs. Geno 1
12-week 7977/IFN regimen looking good for many in ATOMIC study.


12-Week 7977/Riba for G1 HCV
SVR 4 rates vary, depending on IL-28B status.


Hope for Veterans
TMC435 regimen proves useful for prior treatment failures.


AASLD Highlights
News from November's Liver Meeting in S.F.


Abbott Duo Dynamo
ABT-450, ABT-333 interferon-free regimen shows potential.


News for Nulls
PROVIDE study: Victrelis boosts cure rates in prior null responders.


Official EASL
The 2012 International Liver Congress homepage: abstracts, webcasts and more.
NEWSFEED
EASL Coverage

HEP TV
Footage from the front lines
Jose Oliva, MD, an Allegheny General Hospital hepatologist and medical director of the medical center's liver transplant program, speaks with NBC Nightly News about the Hepatitis C epidemic and how it is affecting baby boomers.
PAST CONFERENCE COVERAGE
19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012

AASLD 2011 The Liver Meeting 2011
The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
San Francisco, CA
November 4 - November 8, 2011

EASL 2011 46th Annual Meeting of the European Association for the Study of the Liver
Berlin, Germany
March 30 - April 3, 2011

more conference coverage
© 2013 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.